Archive for October 2015

Andarix and Tulane University Collaborate to Further Research on Mediators of Cancer Cell Signaling

Andarix’ R&D expands to include Notch Influencing Molecules   ANDARIX Pharmaceuticals, a clinical stage company developing targeted peptide therapy for cancers announced today that the Company has entered into an agreement with Tulane University, an institution at the forefront of modern medical innovation, to license the technology and intellectual property concerning Notch Influencing Molecules. The…

Read More